Redburn slashes price target on Moderna Inc. [MRNA] – find out why.


Moderna Inc. [NASDAQ: MRNA] gained 15.97% on the last trading session, reaching $186.49 price per share at the time. The company report on August 3, 2022 that Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24.

Company reiterates advance purchase agreements for expected delivery in 2022 of approximately $21 billion.

Moderna Inc. represents 402.00 million in outstanding shares, while the company has a total market value of $71.43 billion with the latest information. MRNA stock price has been found in the range of $167.74 to $189.33.

If compared to the average trading volume of 5.53M shares, MRNA reached a trading volume of 13737417 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Moderna Inc. [MRNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $221.13 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Redburn have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 01, 2022. The new note on the price target was released on January 26, 2022, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise from $135 to $180, while BofA Securities kept a Neutral rating on MRNA stock.

The Average True Range (ATR) for Moderna Inc. is set at 9.74, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 3.16. The Price to Book ratio for the last quarter was 4.39, with the Price to Cash per share for the same quarter was set at 26.41. Price to Free Cash Flow for MRNA in the course of the last twelve months was 5.48 with Quick ratio for the last quarter at 1.60.

Trading performance analysis for MRNA stock

Moderna Inc. [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.02. With this latest performance, MRNA shares gained by 19.90% in over the last four-week period, additionally plugging by 7.96% over the last 6 months – not to mention a drop of -51.75% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 68.74, with the RSI for the last a single of trading hit 74.03, and the three-weeks RSI is set at 64.80 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 149.88, while it was recorded at 166.19 for the last single week of trading, and 191.54 for the last 200 days.

Moderna Inc. [MRNA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of +71.89 and a Gross Margin at +84.53. Moderna Inc.’s Net Margin is presently recorded at +66.27.

Return on Equity for this stock inclined to 146.08, with Return on Assets sitting at 75.78.

Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.80.

An analysis of insider ownership at Moderna Inc. [MRNA]

There are presently around $46,304 million, or 64.30% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,629,226, which is approximately -0.312% of the company’s market cap and around 5.30% of the total institutional ownership; BLACKROCK INC., holding 28,671,935 shares of the stock with an approximate value of $5.35 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $5.04 billion in MRNA stock with ownership of nearly -1.416% of the company’s market capitalization.

Positions in Moderna Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 489 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 18,701,065 shares. Additionally, 520 investors decreased positions by around 16,723,330 shares, while 162 investors held positions by with 212,869,757 shares. The mentioned changes placed institutional holdings at 248,294,152 shares, according to the latest SEC report filing. MRNA stock had 123 new institutional investments in for a total of 1,625,339 shares, while 183 institutional investors sold positions of 1,561,259 shares during the same period.